Eli Lilly Raises Full Year Outlook amid Q2 2023 Profit Surge of 85%
Eli Lilly’s success can be ascribed in part to its promising medical pipeline and strategic acquisitions.
Eli Lilly Set to Close $2.4B Dice Therapeutics Acquisition to Treat Autoimmune Diseases
By
Tolu Ajiboye
Eli Lilly will spend approximately $2.4 billion acquiring Dice Therapeutics to create more drugs for combating autoimmune diseases.
Eli Lilly and Co Stock Rises 11% as Experimental Alzheimer’s Drug Slows Rate of Decline in Trial
By
Darya Rudz
The next step will be a trial with 500 patients included. Eli Lilly and Co is planning to replicate the results and continue to research the drug’s effectiveness.